Ling Chen

China Life Sciences Access Fund LP is a venture capital fund that operates in the life sciences industry. The private company is based in George Town, Cayman Islands.

Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC.

Peking University provides post-secondary education services. It offers undergraduate and graduate courses. It provides courses such as basic and applied sciences, social sciences and the humanities, sciences of medicine, management, and education. The company was founded by JiaNai Sun in 1898 and is headquartered in Beijing, China.

Legend Capital Co. Ltd (Legend Capital) is a private equity venture capital subsidiary of Legend Holdings Corp. founded in 2001 by Zhu Li Nan. The firm is headquartered in Beijing, China.

Neusoft Medical Systems Co., Ltd. engages in the research, development, manufacturing, and sale of large-scale medical diagnosis and treatment equipment and solutions as well as the provision of related services. Its products include computed tomography systems, magnetic resonance imaging systems, digital subtraction angiography systems, ultrasonic diagnostic equipment, positron emission tomography equipment, radiotherapy products, as well as in vitro diagnostic equipment and reagents. The company was founded on March 6, 1998 and is headquartered in Shenyang, China.

Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China.

6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017.

Part of Kenvue, Inc., Johnson & Johnson China Ltd. is a Chinese company that manufactures pharmaceutical products. The company is based in Shanghai, China.

Part of Al Nawwar Investments RSC Ltd., Sequoia Capital China Investment Management LP operates as an investment holding Chinese company.

Fog Pharmaceuticals, Inc. develops pharmaceutical products. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane and is headquartered in Cambridge, MA.

TenNor Therapeutics Suzhou Ltd. manufactures pharmaceutical products. It specializes in research and development of new drugs for the treatment of digestive diseases caused by pathogens, including those resistant to available antibiotics. The company was founded by Zhen Kun Ma in 2013 and is headquartered in Suzhou, China.

Hisun Pfizer Pharmaceuticals Co., Ltd. engages in the development, production, marketing, and sale of pharmaceutical products. It offers medicine in the form of tablets, hard capsules, and injection. The company was founded on September 6, 2012 and is headquartered in Hangzhou, China.

Xiamen LP Pharmaceutical Co., Ltd. engages in the development of improved new drugs. It provides perfluoropropane human albumin microspheres for injection, pramipexole hydrochloride sustained-release tablets, and clonidine hydrochloride sustained-release tablets. The company was founded by Ying Ye and Cheng Ye on November 2, 2012 and is headquartered in Xiamen, China.

Engine Biosciences Pte Ltd. develops novel combinations of genes and drugs for therapeutic and industrial purposes. The company was founded by Timothy Lu and Jeffrey Lu and is headquartered in Singapore.

Tengsheng Boyao Pharmaceutical Technology Shanghai Co., Ltd. engages in research and development of medical technology. The company was founded by Zhi Hong on April 19, 2018 and is headquartered in Shanghai, China.

Tongrun Biomedicine (Shanghai) Co., Ltd. develops tumor immunotherapy drugs. The company is based in Shanghai, China.

Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then.

Sironax Ltd. is a clinical-stage biotechnology company located in Beijing, China. The Chinese company is dedicated to discovering and developing novel treatments for patients with age-related degenerative diseases. Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. Currently, Sironax is conducting early clinical studies with sir0365 and sir2446, in addition to ongoing preclinical research.

AccuMedical Beijing Ltd. engages in developing and manufacturing medical devices. Its products include flow re-direction system, microcatheter and distal access catheter. The company was founded by Yi Ran Lu on August 29 , 2017 and is headquartered in Beijing, China.

Qianglian Zhichuang (Beijing) Technology Co., Ltd. is based in Beijing, China. Qianglian Zhichuang (Beijing) Technology Co., Ltd. provides intelligent auxiliary diagnosis and treatment solutions for neurological diseases. The Chinese company was founded in 2016 by Lan Qin and Wen Zhe Liu. Wen Zhe Liu has been the CEO since 2016.

Jiutian Biopharmaceutical (Shanghai) Co., Ltd. is a Chinese biotechnology company founded in 2019. The company operates in the field of biotechnology and is based in Shanghai, CN. It is worth noting that the company has subsidiaries in Cayman Islands and United States.

MicroPort Cardiac Rhythm Management International Ltd. operates as a commercial-stage medical technology company. It specializes in active implantable medical devices for cardiac rhythm management. The firm's product portfolio covers a CRM devices, including low-voltage CRM devices, namely, pacemakers (for abnormally slow heart rate, or bradycardia) and cardiac re-synchronization therapy pacemakers, high-voltage CRM devices, namely, implantable cardioverter defibrillators (ICD) and cardiac re-synchronization therapy defibrillators (CRT-D), CRM patient monitoring devices and arrhythmia diagnostic devices. The company was founded on September 10, 2019 and is headquartered in Hong Kong.